Bristol-Myers Squibb has made a $35 million equity investment in Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies. Additionally, BMS has the right to appoint a member to the Immatics Scientific Advisory Board.   Immatics combines the discovery of targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against thes...